#12 MINUTES MINDFULNESS ACHIEVEMENT FULL#

The results revealed similar between-group drop-out rates, and greater improvements in headache frequency and non-steroidal anti-inflammatory drugs (NSAIDs) intake among patients randomized to receiving mindfulness session added to TaU (TaU + MIND) compared to TaU. In a preliminary report from the present study, the MIND-CM study, we presented the feasibility and short-term efficacy of the proposed mindfulness-based protocol as an add-on to treatment as usual (TaU). The two groups performed similarly for migraine and headache days/month changes, and patients assigned to MBSR showed superior improvements in secondary outcomes such as disability or quality of life (QoL). Wells and colleagues followed-up for 36 weeks 89 patients with migraine (baseline frequency: 4–20 days/month) who were randomized to either education or mindfulness-based stress reduction (MBSR) therapy. įew randomized-controlled trials (RCTs) have been carried out to test the efficacy of mindfulness-based approaches.

#12 MINUTES MINDFULNESS ACHIEVEMENT FULL#

Mindfulness treatments are aimed to master patients’ ability to intentionally paying attention to the present moment, in a non-judgmental way, so to enable cultivating a full presence in the experience of the moment.

Among these, mindfulness-based approaches received attention, and some recent reviews concluded that they may be beneficial, with effects comparable to pharmacological treatments. Both pharmacological and non-pharmacological treatments are available. Patients with CM and MOH experience relevant pain, limitations in daily activities, personal and societal disease burden. MIND-CM was registered on (NCT03671681) on.Ĭhronic Migraine (CM) associated to Medication Overuse Headache (MOH) is characterized by 15 or more days with headache per month and by the overuse of acute medications for at least three months. ConclusionsĪ mindfulness-based treatment composed of six-week session and 7–10 min daily self-practice added on to TaU is superior to TaU alone for the treatment of patients with CM and MOH. 48.3% p < 0.0001), and showed superior improvement in headache frequency, QoL and disability, headache impact, loss of productive time, medication intake, and in total, indirect and direct healthcare costs.

Patients in the TaU + MIND group outperformed those in TaU for the primary endpoint (78.4% vs. Out of the 177 participants 89 were randomized to TaU and 88 to TaU + MIND. The secondary endpoints were analyzed using per-protocol linear mixed models. Secondary endpoints included medication intake, quality of life (QoL), disability, depression and anxiety, cutaneous allodynia, awareness of inner states, work-related difficulties, and disease cost. The primary endpoint was the achievement of ≥ 50% headache frequency reduction at 12 months compared to baseline, and was analyzed on an intention-to-treat principle using Pearson’s Chi-Squared test. The mindfulness-based intervention consisted of six group session of mindfulness practice and 7–10 min daily self-practice. In this Phase-III single-blind RCT carried out in a specialty Italian headache center, 177 patients with CM and MOH were randomized 1:1 to either TaU (withdrawal from overused drugs, education on proper medication use and lifestyle issues, and tailored prophylaxis) or mindfulness-based intervention added to TaU (TaU + MIND). We aimed to assess the efficacy of a six-sessions mindfulness-based treatment added to treatment as usual (TaU) in patients with Chronic Migraine (CM) and Medication Overuse Headache (MOH) on headache frequency, medication intake, quality of life, disability, depression and anxiety, cutaneous allodynia, awareness of inner states, work-related difficulties, and disease cost. Mindfulness gained considerable attention for migraine management, but RCTs are lacking.

12 minutes mindfulness achievement